Business · 28/06/2022

FDA Releases Final Guidance for Bladder Cancer Adjuvant Treatment Development

The Food and Drug Administration (FDA) has released a final guidance for the development of drugs and biologics for treating muscle-invasive bladder cancer as an adjuvant treatment. The guidance provides recommendations for sponsors on key aspects of the treatment, including eligibility criteria and trial results interpretation.